Morgan Stanley Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained its Overweight rating on Intra-Cellular Therapies and raised the price target from $92 to $95, indicating a positive outlook for the company's stock.
October 11, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has increased its price target for Intra-Cellular Therapies from $92 to $95 while maintaining an Overweight rating, suggesting a positive short-term outlook for the stock.
The increase in price target by Morgan Stanley, along with the maintained Overweight rating, indicates confidence in Intra-Cellular Therapies' future performance. This is likely to positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100